ライフサイエンスコーパス: catecholaminergic

1 and many of these presympathetic neurons are catecholaminergic.

2 k tyrosine hydroxylase (TH) and thus are not catecholaminergic.

3 beta-hydroxylase, indicating that they were catecholaminergic.

4 abeled neurons were either serotoninergic or catecholaminergic.

5 GABAergic, non-glycinergic and predominantly catecholaminergic (54%).

6 b) the dynamic properties of growth cones in catecholaminergic a-differentiated neuroblastoma cells.

7 Results indicate that AMPK in catecholaminergic A1-C1m neurons is activated by glucopr

8 ls in transgenic mice in which both types of catecholaminergic amacrine (CA) cells were labeled with

9 by reserpine indicate that these nerves are catecholaminergic and are required for functional inhibi

10 Among these are several catecholaminergic and cholinergic cell groups, the peria

11 The activation of catecholaminergic and hypothalamic-pituitary-adrenal axi

12 Both catecholaminergic and noncatecholaminergic neurons conta

13 rochemistry (using in situ hybridization) of catecholaminergic and noncatecholaminergic neurons which

14 e properties of unmodified human MSCs on rat catecholaminergic and serotonergic cell cultures exposed

15 TH(-) neurons but spared facial motoneurons, catecholaminergic and serotonergic neurons and the ventr

16 BS-NSC graft-derived catecholaminergic and serotonergic neurons showed remark

17 and sparse projections were observed in many catecholaminergic and serotonergic nuclei, as well as th

18 may be expressed in a few subpopulations of catecholaminergic and serotoninergic neurons in the carp

19 mportantly, analysis of GFP in the zebrafish catecholaminergic areas revealed the same expression pat

20 tilization, GFP began expressing in distinct catecholaminergic areas.

21 In the absence of aFGF+ChABC fewer catecholaminergic axons entered the graft, no axons exit

22 ns were counterstained with Cuprolinic Blue; catecholaminergic axons were stained immunohistochemical

23 s, allowing for robust growth, especially of catecholaminergic axons, through the graft and back into

24 Hydroxylase (Dbh), a gene encoding a crucial catecholaminergic biosynthetic enzyme.

25 m BAT combined with immunohistochemistry for catecholaminergic biosynthetic enzymes revealed the vent

26 ent of ventral medullary sympatho-excitatory catecholaminergic C1 neurons, using inhibitory Drosophil

27 ine hydroxylase (TH) to identify bulbospinal catecholaminergic (C1) neurons in sedentary and active r

28 Although the neuroanatomical distribution of catecholaminergic (CA) neurons has been well documented

29 Catecholaminergic (CA) neurons innervate sensory areas a

30 Developmental studies of the central catecholaminergic (CA) system are essential for understa

31 Kalpha) in hindbrain micropunches containing catecholaminergic cell groups A1 through the middle regi

32 Catecholaminergic cell groups in the pons (LC) and medul

33 we hypothesized that during song perception, catecholaminergic cell groups of the brainstem actively

34 that estradiol induces changes in brainstem catecholaminergic cell groups that may play a neuromodul

35 Additional assays were performed on a catecholaminergic cell line and animal models of iron de

36 novel plasminogen receptor, and its role in catecholaminergic cell plasminogen activation and regula

37 mary, Plg-R(KT) is present on the surface of catecholaminergic cells and functions to stimulate plasm

38 We discover neural crest-derived catecholaminergic cells associated with zebrafish pharyn

39 Here, we investigated the role of brainstem catecholaminergic cells groups, which project to the for

40 auditory forebrain as well as the number of catecholaminergic cells in the locus coeruleus (A6) and

41 Neurotransmitter release by catecholaminergic cells is negatively regulated by proho

42 r connectivity and alternating activity, the catecholaminergic cells may generate the rhythm.

43 Distinct groups of catecholaminergic cells were observed in the olfactory b

44 the AMPK-alpha1 and/or AMPK-alpha2 genes in catecholaminergic cells, which compose the hypoxia-respo

45 al plasma membrane protein on the surface of catecholaminergic cells.

46 her with epinephrine and norepinephrine from catecholaminergic cells.

47 minogen activation was enhanced >6.5-fold on catecholaminergic cells.

48 Activation of medullary catecholaminergic centers might reflect the afferent and

49 Ventricular arrhythmias evoked by catecholaminergic challenge (caffeine/adrenaline) in S28

50 via the aggregation of neural crest-derived catecholaminergic (chromaffin) cells already associated

51 We identified cholinergic, serotonergic, and catecholaminergic ciliomotor neurons.

52 ng neural pathways including both a distinct catecholaminergic "danger" pathway, and a possibly multi

53 mRNA and protein levels, and thereby central catecholaminergic-dependent behavioral pathways.

54 nd noradrenaline) and review the efficacy of catecholaminergic drugs in treating post-traumatic brain

55 The findings support the notion of catecholaminergic dysfunction as a possible trait abnorm

56 pose of this study was to examine a possible catecholaminergic dysfunction in the pathogenesis of bul

57 Cortical TH cells lack all additional catecholaminergic enzymes, and many coexpress GABA and c

58 cells reportedly fail to produce subsequent catecholaminergic enzymes, we found that the majority of

59 nsferase (Pnmt), which also encode essential catecholaminergic enzymes, were severely reduced in post

60 ACCs, we show here that less than 10% of all catecholaminergic exocytosis, measured by carbon fibre a

61 ytosis as they do in the case of spontaneous catecholaminergic exocytosis.

62 e of NPY coexpression within interneurons or catecholaminergic fibers with somatostatin and tyrosine

63 tors included calcium , drugs modulating the catecholaminergic fight-or-flight stress response such a

64 way to investigate the relationship between catecholaminergic function and psychiatric disorder has

65 model simulations indicating that increasing catecholaminergic gain should reduce the angular dispers

66 More striking, we find that nearly all non-catecholaminergic glutamatergic neurons of the ventrolat

67 e suprachiasmatic area was identified by its catecholaminergic groups and the lack of Otp, and could

68 l together, our results demonstrate that all catecholaminergic groups in zebrafish are either GABAerg

69 at select wake neurons, specifically the two catecholaminergic groups, can be rendered persistently i

70 in line with a model in which stress-induced catecholaminergic hyperactivation alters phasic neuromod

71 eurons originates predominantly from PNMT-ir catecholaminergic (i.e., C1 cells).

72 2808A+/+ mice were protected against chronic catecholaminergic-induced cardiac dysfunction.

73 tment significantly increased the density of catecholaminergic innervation of the auditory forebrain

74 ypothesized that estradiol treatment affects catecholaminergic innervation of the auditory forebrain

75 Catecholaminergic inotropes have a place in the manageme

76 tter neurons are part of a larger network of catecholaminergic input to neuroendocrine neurons in the

77 d the ventrolateral medulla as the source of catecholaminergic input to the rRPa and demonstrated tha

78 or the existence of a population of putative catecholaminergic interneurons in the associative territ

79 own anole brain and demonstrate evidence for catecholaminergic involvement in appetitive and consumma

80 ehaviour, and helps refine current models of catecholaminergic modulation of motivated action.

81 stem components; it is therefore likely that catecholaminergic molecular components influence the eff

82 face density and decreased cell viability in catecholaminergic N2a cells.

83 In NGF-differentiated PC12 catecholaminergic nerve cells, we show that de novo expr

84 we analyzed the spatial relationship between catecholaminergic neural fibers and sites of simian immu

85 sed social stress can enhance the density of catecholaminergic neural fibers within axillary lymph no

86 t the hypothesis that they are shaped by the catecholaminergic neuromodulators norepinephrine and dop

87 Potential candidate factors are subcortical catecholaminergic neuromodulatory systems, such as the l

88 cholaminergic neurons and a few PPE positive catecholaminergic neuron but neurochemical codes were la

89 lrhodopsin-2 (ChR2) under the control of the catecholaminergic neuron-preferring promoter PRSx8 was i

90 rotein ChR2-mCherry under the control of the catecholaminergic neuron-selective promoter PRSx8 and ob

91 Treatment of catecholaminergic neuronal cell lines (B65 and SH-SY5Y)

92 e hydroxylase, revealing the distribution of catecholaminergic neurons (dopaminergic, noradrenergic,

93 genetics in tissue slices, we show that RVLM catecholaminergic neurons activate the locus coeruleus a

94 se parkin, resulting in neurodegeneration of catecholaminergic neurons and a familial form of Parkins

95 on and migration of neuronal progenitors for catecholaminergic neurons and interneurons.

96 Not all catecholaminergic neurons are activated and other neuroc

97 Thus, the majority of catecholaminergic neurons are gad1b/2-positive and coexp

98 ure rats revealed that microglia surrounding catecholaminergic neurons are in a "surveillance" state

99 ep apnea; wake impairments are irreversible; catecholaminergic neurons are lost; and neuronal NADPH o

100 nput to the rRPa and demonstrated that these catecholaminergic neurons are synaptically connected to

101 We tested the hypothesis that NTS catecholaminergic neurons attenuate psychological stress

102 ctively expressed ChR2(H134R) in rostral VLM catecholaminergic neurons by injecting Cre-dependent ade

103 vidence that the axons of rostral VLM (RVLM) catecholaminergic neurons contact locus coeruleus, A1, a

104 s of glutamate, PACAP, and microglia on RVLM catecholaminergic neurons during the cardiovascular resp

105 It may be possible to protect catecholaminergic neurons from reactive oxygen species-i

106 ated sensory information activates hindbrain catecholaminergic neurons in a rate-dependent manner.

107 zenk, a putative marker of activity, within catecholaminergic neurons in any of the cell groups quan

108 cle was microinjected into the NTS to lesion catecholaminergic neurons in male Sprague-Dawley rats, a

109 a useful strategy to reduce degeneration of catecholaminergic neurons in Parkinson's disease.

110 n suggested to underlie the vulnerability of catecholaminergic neurons in Parkinson's disease.

111 wed us to ascribe a role for ghrelin-engaged catecholaminergic neurons in stress-induced eating.

112 ir in common somatodendritic compartments of catecholaminergic neurons in the LC, and also revealed C

113 to be propagated via specific populations of catecholaminergic neurons in the NTS and VLM, and likely

114 These data indicate that catecholaminergic neurons in the NTS are poised to simul

115 The catecholaminergic neurons in the rostral ventrolateral m

116 ENT C1 neurons are glutamatergic/peptidergic/catecholaminergic neurons located in the medulla oblonga

117 Also, signaling specifically in catecholaminergic neurons mediated not only ghrelin's or

118 The data suggest that NTS catecholaminergic neurons normally inhibit the arterial

119 medium spiny neurons of the striatum and the catecholaminergic neurons of the substantia nigra and lo

120 iciency leads to the premature demise of the catecholaminergic neurons of the ventral midbrain in fam

121 dorsal motor nucleus of the vagus [DMN] and catecholaminergic neurons of the ventrolateral medulla [

122 Brainstem catecholaminergic neurons play key roles in the autonomi

123 These likely include PPNPY expressing catecholaminergic neurons projecting to vasopressinergic

124 Degeneration of catecholaminergic neurons remains unchanged by PrP(C) re

125 We tested in male rats whether catecholaminergic neurons that project to the medial and

126 Both transcripts were detected in catecholaminergic neurons throughout the CNS.

127 , we confirmed that the projection from RVLM catecholaminergic neurons to the orexinergic neurons ori

128 RTN and catecholaminergic neurons were transduced.

129 Catecholaminergic neurons within the central nervous sys

130 ual immunostaining for tyrosine hydroxylase (catecholaminergic neurons) and c-Fos (marker of neuronal

131 of the VLM, including a large proportion of catecholaminergic neurons, but no colocalization of sst2

132 range of stimuli activate neurons, including catecholaminergic neurons, in the ventrolateral medulla.

133 synthesis, can be inducibly downregulated in catecholaminergic neurons, including those of the SN.

134 ral wake-promoting systems (serotonergic and catecholaminergic neurons, orexinergic neurons) are also

135 In conclusion, activation of RVLM catecholaminergic neurons, predominantly C1 cells, by so

136 membrane and mitochondria of astrocytes and catecholaminergic neurons, suggesting that it plays a ro

137 hypoglycemia require hypothalamus-projecting catecholaminergic neurons, the majority of which origina

138 INSPAReDT ablates peripheral but not central catecholaminergic neurons, thus avoiding the Parkinson-l

139 s than 2-deoxyglucose but similar numbers of catecholaminergic neurons.

140 where VMH efferents make close contacts with catecholaminergic neurons.

141 butyric acid (GABA)ergic, glutamatergic, and catecholaminergic neurons.

142 eversed by selective reactivation of GHSR in catecholaminergic neurons.

143 xygenation exposures conferred protection of catecholaminergic neurons.

144 on of tyrosine hydroxylase (TH), a marker of catecholaminergic neurons.

145 stidine-tagged alpha-synuclein isolated from catecholaminergic neurons.

146 act afferents originating from hindbrain CA (catecholaminergic) neurons, the identity of these signal

147 Here, we examined catecholaminergic neurosecretory cells for expression, t

148 ess reward-effort integration in relation to catecholaminergic neurotransmission at the behavioral an

149 on, of Phox2b-expressing, glutamatergic, non-catecholaminergic, noncholinergic neurons located in the

150 ignals from the NTS are communicated by both catecholaminergic [norepinephrine (NE), epinephrine (E)]

151 ulation of five heritable transcripts in the catecholaminergic pathway in young (6 weeks) SHRs.

152 to the fourth ventricle does not act through catecholaminergic pathways.

153 s to permit sympathetic neurons to acquire a catecholaminergic phenotype.

154 retrotrapezoid nucleus (RTN), a group of non-catecholaminergic Phox2b-expressing central respiratory

155 s the transcription factor Phox2b and is non-catecholaminergic (Phox2b(+)TH(-)).

156 sis (17%), including Long-QT syndrome (13%), catecholaminergic polymorphic ventricular tachycardia (4

157 Catecholaminergic polymorphic ventricular tachycardia (C

158 present with divergent clinical features of catecholaminergic polymorphic ventricular tachycardia (C

159 Long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (C

160 Catecholaminergic polymorphic ventricular tachycardia (C

161 ne receptor (RyR2) mutations associated with catecholaminergic polymorphic ventricular tachycardia (C

162 es associated with sudden death-predisposing catecholaminergic polymorphic ventricular tachycardia (C

163 Catecholaminergic polymorphic ventricular tachycardia (C

164 Catecholaminergic polymorphic ventricular tachycardia (C

165 Catecholaminergic polymorphic ventricular tachycardia (C

166 ced pluripotent stem cells (hiPSCs) model of catecholaminergic polymorphic ventricular tachycardia (C

167 lymorphic ventricular tachycardia in humans [catecholaminergic polymorphic ventricular tachycardia (C

168 es, we propose a molecular mechanism for the catecholaminergic polymorphic ventricular tachycardia (C

169 ing that point mutation R33Q leads to lethal catecholaminergic polymorphic ventricular tachycardia (C

170 yanodine Receptor gene (RYR2) cause dominant catecholaminergic polymorphic ventricular tachycardia (C

171 e of arrhythmogenic Ca(2+) release events in catecholaminergic polymorphic ventricular tachycardia (C

172 Catecholaminergic polymorphic ventricular tachycardia (C

173 Mutations in RYR2 cause type 1 catecholaminergic polymorphic ventricular tachycardia (C

174 ed with severe forms of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia (C

175 sm of therapeutic efficacy of flecainide for catecholaminergic polymorphic ventricular tachycardia (C

176 cardiac RyR (RyR2) mutations associated with catecholaminergic polymorphic ventricular tachycardia (C

177 Catecholaminergic polymorphic ventricular tachycardia (C

178 In catecholaminergic polymorphic ventricular tachycardia (C

179 associated with atrial fibrillation (AF) and catecholaminergic polymorphic ventricular tachycardia (C

180 Catecholaminergic polymorphic ventricular tachycardia (C

181 d mutations in CaM cause arrhythmias such as catecholaminergic polymorphic ventricular tachycardia (C

182 Current mechanisms of arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia (C

183 ch as congenital long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (C

184 Catecholaminergic polymorphic ventricular tachycardia (C

185 spectrum of arrhythmogenic disease included catecholaminergic polymorphic ventricular tachycardia (n

186 Patients with LQTS (N=40) and catecholaminergic polymorphic ventricular tachycardia (N

187 rillator (ICD) therapy for the management of catecholaminergic polymorphic ventricular tachycardia (V

188 rdiac arrest, including long-QT syndrome and catecholaminergic polymorphic ventricular tachycardia (V

189 Catecholaminergic polymorphic ventricular tachycardia (V

190 ence (10; 21%) and disease factors (18; 38%; catecholaminergic polymorphic ventricular tachycardia [6

191 ed to exercise-induced sudden cardiac death (catecholaminergic polymorphic ventricular tachycardia [C

192 netic form of exercise-induced sudden death (catecholaminergic polymorphic ventricular tachycardia [C

193 Our data highlighted the predominant role of catecholaminergic polymorphic ventricular tachycardia an

194 The main etiologies established were catecholaminergic polymorphic ventricular tachycardia an

195 rited and acquired cardiac diseases, such as catecholaminergic polymorphic ventricular tachycardia an

196 Foremost are those with catecholaminergic polymorphic ventricular tachycardia du

197 (2/10) and 50% of long QT syndrome (1/2) and catecholaminergic polymorphic ventricular tachycardia fa

198 ism of Ca(2+) release dysfunction underlying catecholaminergic polymorphic ventricular tachycardia ha

199 Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in

200 The recessive form of catecholaminergic polymorphic ventricular tachycardia is

201 ardiac calsequestrin-2 gene; this variant of catecholaminergic polymorphic ventricular tachycardia is

202 Catecholaminergic polymorphic ventricular tachycardia is

203 Catecholaminergic polymorphic ventricular tachycardia is

204 Catecholaminergic polymorphic ventricular tachycardia is

205 Catecholaminergic polymorphic ventricular tachycardia is

206 Catecholaminergic polymorphic ventricular tachycardia is

207 Catecholaminergic polymorphic ventricular tachycardia is

208 Patients with catecholaminergic polymorphic ventricular tachycardia ma

209 e-threatening arrhythmias in CASQ2-defective catecholaminergic polymorphic ventricular tachycardia mi

210 ed properties not previously identified in a catecholaminergic polymorphic ventricular tachycardia mo

211 ntials and diastolic contractions (DCs) in a catecholaminergic polymorphic ventricular tachycardia mo

212 injection, analogous to what was observed in catecholaminergic polymorphic ventricular tachycardia pa

213 tions contributing to the SAN dysfunction in catecholaminergic polymorphic ventricular tachycardia pa

214 y multicenter, retrospective cohort study of catecholaminergic polymorphic ventricular tachycardia pa

215 patients diagnosed with long QT syndrome and catecholaminergic polymorphic ventricular tachycardia re

216 nelopathies (short and long QT, Brugada, and catecholaminergic polymorphic ventricular tachycardia sy

217 DEP and sudden cardiac death cases linked to catecholaminergic polymorphic ventricular tachycardia th

218 Catecholaminergic polymorphic ventricular tachycardia ty

219 A specific genetic test for catecholaminergic polymorphic ventricular tachycardia wa

220 ogenic right ventricular cardiomyopathy, and catecholaminergic polymorphic ventricular tachycardia we

221 ic arrhythmia syndromes (e.g., flecainide in catecholaminergic polymorphic ventricular tachycardia).

222 /18 (72%); long QT syndrome, 3/18 (17%); and catecholaminergic polymorphic ventricular tachycardia, 2

223 s (long QT syndrome, 9; Brugada syndrome, 8; catecholaminergic polymorphic ventricular tachycardia, 3

224 practicing cardiologists: long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, a

225 ac calsequestrin (CASQ2) genes are linked to catecholaminergic polymorphic ventricular tachycardia, a

226 thal cardiac arrhythmia syndromes, including catecholaminergic polymorphic ventricular tachycardia, c

227 In catecholaminergic polymorphic ventricular tachycardia, e

228 es have been used to study long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, h

229 we simulated mutations in 2 genes linked to catecholaminergic polymorphic ventricular tachycardia, t

230 l and structural properties of wild-type and catecholaminergic polymorphic ventricular tachycardia-as

231 AN [Ca(2+)](i) handling in mice carrying the catecholaminergic polymorphic ventricular tachycardia-li

232 iac myocytes of heterozygous mice carrying a catecholaminergic polymorphic ventricular tachycardia-li

233 tibility genes (KCNQ1, KCNH2, and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-su

234 r in heart failure, cardiac hypertrophy, and catecholaminergic polymorphic ventricular tachycardia.

235 rt diseases, such as the long-QT syndrome or catecholaminergic polymorphic ventricular tachycardia.

236 a variety of cardiac arrhythmias, including catecholaminergic polymorphic ventricular tachycardia.

237 ch as long QT syndrome, Brugada Syndrome, or Catecholaminergic Polymorphic Ventricular Tachycardia.

238 o provide a new arrhythmogenic mechanism for catecholaminergic polymorphic ventricular tachycardia.

239 syncope in his brother raised suspicion for catecholaminergic polymorphic ventricular tachycardia.

240 receptor-2 mutation that was consistent with catecholaminergic polymorphic ventricular tachycardia.

241 ng neighboring myocytes, and correlated with catecholaminergic polymorphic ventricular tachycardia.

242 ethylenedioxymethamphetamine, marijuana, and catecholaminergic polymorphic ventricular tachycardia.

243 ctric dysfunction in an established model of catecholaminergic polymorphic ventricular tachycardia.

244 me, short QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia.

245 at position 307 in CASQ2 has been linked to catecholaminergic polymorphic ventricular tachycardia.

246 phenotype and lengthy delay to diagnosis in catecholaminergic polymorphic ventricular tachycardia.

247 o define treatment outcomes in children with catecholaminergic polymorphic ventricular tachycardia.

248 reduces risk in long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia.

249 t cardiac sympathetic denervation in LQTS or catecholaminergic polymorphic ventricular tachycardia.

250 : 14 Brugada syndrome; 4 long-QT syndrome; 1 catecholaminergic polymorphic ventricular tachycardia; a

251 retrospective review of young patients with catecholaminergic polymorphic VT and ICDs from 5 centers

252 ICD efficacy in catecholaminergic polymorphic VT depends on arrhythmia m

253 Catecholaminergic polymorphic VT is caused by enhanced C

254 17% of long-QT syndrome patients and 13% of catecholaminergic polymorphic VT patients.

255 edian (interquartile range) ages at onset of catecholaminergic polymorphic VT symptoms and ICD implan

256 Catecholaminergic polymorphic VT was diagnosed if epinep

257 Testing for catecholaminergic polymorphic VT was positive in 7% and

258 ncluding long QT syndrome, Brugada syndrome, catecholaminergic polymorphic VT, and short QT syndrome.

259 R4496C+/-) by crossbreeding PLN-KO mice with catecholaminergic polymorphic VT-associated RyR2-R4496C

260 s and stress-induced VTs in a mouse model of catecholaminergic polymorphic VT.

261 of cardiac ryanodine-receptor (RyR2)-linked catecholaminergic polymorphic VT.

262 an important source of focal arrhythmias in catecholaminergic polymorphic VT.

263 investigate the arrhythmogenic mechanisms in catecholaminergic polymorphic VT.

264 support a specific involvement of ascending catecholaminergic projections in mediating PVH responses

265 We conclude that 1) catecholaminergic projections to the hypothalamus provid

266 the lateral BST, and the CEA, and mostly non-catecholaminergic projections to the PBL.

267 all four regions, via direct, predominantly catecholaminergic, projections to the PVN, the lateral B

268 ular tachycardia and sudden cardiac death on catecholaminergic provocation by caffeine/epinephrine or

269 Catecholaminergic responses may be partially genetic and

270 To evaluate catecholaminergic responses without systemic counterregu

271 ctivation of rostral ventrolateral medullary catecholaminergic (RVLM-CA) neurons e.g., by hypoxia is

272 hether these rostral ventrolateral medullary catecholaminergic (RVLM-CA) neurons use glutamate as a t

273 We used an adenoviral vector with a catecholaminergic-selective promoter (AVV-PRS) to retrog

274 acilitation of "top-down" control, excessive catecholaminergic stimulation, and subcortical imbalance

275 ) release channel and greatly exacerbated by catecholaminergic stimulation, with the development of a

276 eart rate and contractile responses to acute catecholaminergic stimulation.

277 first comprehensive and detailed map of the catecholaminergic structures in the brain of two represe

278 ry analysis of postmortem samples that human catecholaminergic substantia nigra and locus coeruleus n

279 ons, including glutamatergic, GABAergic, and catecholaminergic subtypes.

280 th norepinephrine and caffeine to simulate a catecholaminergic surge, Scn8a(N1768D/+) mice showed ven

281 The results suggest novel links among the catecholaminergic system, oxidative pathways, and system

282 ter biosynthesis, storage and release in the catecholaminergic system.

283 associated with dysregulation of the central catecholaminergic system.

284 iated neural circuits reveals defects in the catecholaminergic system.

285 the potential to identify disruption to the catecholaminergic systems and to provide a direct measur

286 Catecholaminergic systems in the brain are among the mos

287 ing the structure and function of a person's catecholaminergic systems is likely to allow more refine

288 appears to be a regular feature of zebrafish catecholaminergic systems.

289 Transiently catecholaminergic (TC), neural crest-derived precursors

290 vested effort involves mechanisms related to catecholaminergic transmission and a suppression of DMN

291 und in chromaffin granules, we conclude that catecholaminergic transmitter systems have the potential

292 ion increased by 3.9-fold in the vicinity of catecholaminergic varicosities (P < 0.0001).

293 idization for SIV env, gag, and nef RNA, and catecholaminergic varicosities from the ANS were mapped

294 c calsequestrin-null mice (Casq2-/-) display catecholaminergic ventricular tachycardia akin to humans

295 at CAPS/UNC-31 function is not restricted to catecholaminergic vesicles but is generally required for

296 /reoxygenation, the role of NADPH oxidase in catecholaminergic vulnerability was next addressed.

297 lytic and cytosolic subunits were evident in catecholaminergic wake neurons, where hypoxia/reoxygenat

298 oxia/reoxygenation resulted in a 40% loss of catecholaminergic wake neurons.

299 e obstructive sleep apnea in humans destroys catecholaminergic wake neurons.

300 PPPACAP, and PPNPY mRNAs, which were largely catecholaminergic, were activated by hydralazine but not